Astera Labs (ALAB) CEO receives 26,522 RSUs and reports major trust holdings

Rhea-AI Filing Summary

Astera Labs, Inc. reported an equity grant to its Chief Executive Officer and director, Mohan Jitendra. On February 6, 2026, he received 26,522 shares of common stock as restricted stock units at $0 per share under the 2024 Stock Option and Incentive Plan.

The RSUs vest as to 25% on February 15, 2027, with the remaining units vesting in 12 equal quarterly installments, contingent on continued service. Following this grant, he directly holds 1,547,710 shares of common stock. Additional common shares are held indirectly through a living trust and several estate-planning trusts that are associated with him, for which he disclaims beneficial ownership except for any pecuniary interest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mohan Jitendra

(Last) (First) (Middle)

C/O ASTERA LABS, INC.

2345 NORTH FIRST STREET

(Street)

SAN JOSE CA 95131

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Astera Labs, Inc. [ ALAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/06/2026		A		26,522(1)	A	$0	1,547,710	D
Common Stock								4,689,232	I	By Living Trust(2)
Common Stock								699,999	I	By Trust(3)
Common Stock								700,000	I	By 2021 Trust 1(4)
Common Stock								700,000	I	By 2021 Trust 2(5)
Common Stock								450,001	I	By 2022 Trust 1(6)
Common Stock								450,001	I	By 2022 Trust 2(7)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares represent an award of restricted stock units ("RSUs") granted on February 6, 2026 under the Astera Labs, Inc. 2024 Stock Option and Incentive Plan. Such award provides that the RSUs shall vest as to 25% on February 15, 2027 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

2. These shares are owned directly by a living trust (the "Living Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

3. These shares are owned directly by an estate planning trust (the "Trust"). The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

4. These shares are owned directly by an estate planning trust (the "2021 Trust 1"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

5. These shares are owned directly by an estate planning trust (the "2021 Trust 2"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

6. These shares are owned directly by an estate planning trust (the "2022 Trust 1"). The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

7. These shares are owned directly by an estate planning trust (the "2022 Trust 2"). The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Remarks:

	/s/ Philip Mazzara, Attorney-in-Fact	02/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Astera Labs (ALAB) disclose for Mohan Jitendra?

Astera Labs disclosed that CEO and director Mohan Jitendra received 26,522 restricted stock units on February 6, 2026. These RSUs convert into common shares over time, providing equity-based compensation linked to his ongoing service with the company.

How do the 26,522 RSUs for Astera Labs (ALAB) CEO vest over time?

The 26,522 RSUs granted to Astera Labs’ CEO vest 25% on February 15, 2027. The remaining units vest in 12 equal quarterly installments thereafter, conditioned on his continuous service relationship with the company at each vesting date.

What is Mohan Jitendra’s direct common stock holding in Astera Labs (ALAB) after this grant?

After the February 6, 2026 grant, Mohan Jitendra directly holds 1,547,710 shares of Astera Labs common stock. This direct position is in addition to various indirect holdings through trusts that are associated with his estate and financial planning.

What indirect Astera Labs (ALAB) shareholdings are associated with trusts linked to the CEO?

Several trusts associated with the CEO hold Astera Labs common stock, including a living trust with 4,689,232 shares and multiple estate-planning trusts with holdings such as 699,999 and 700,000 shares. He disclaims beneficial ownership except for any pecuniary interest.

Does the Astera Labs (ALAB) CEO claim full beneficial ownership of shares held in related trusts?

No. For shares held by the living trust and estate-planning trusts, the CEO disclaims beneficial ownership except to the extent of any pecuniary interest. The filing clarifies these positions are held by the trusts, even where he may serve as trustee.

What stock plan governed the 26,522 RSU grant at Astera Labs (ALAB)?

The 26,522 RSUs granted to the Astera Labs CEO were issued under the Astera Labs, Inc. 2024 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the company’s common stock upon vesting.